Boston Scientific Corporation (NYSE:BSX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Boston Scientific Corporation (NYSE:BSX) have received an average rating of “Moderate Buy” from the twenty-seven brokerages that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, twenty-three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $92.2917.

Several analysts have commented on the stock. Stifel Nicolaus set a $75.00 price target on shares of Boston Scientific in a research note on Wednesday. Bank of America decreased their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Robert W. Baird decreased their target price on shares of Boston Scientific from $78.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Raymond James Financial restated an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Finally, Evercore decreased their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Boston Scientific cut its 2026 growth outlook and signaled softer demand in WATCHMAN and urology, raising concerns that near-term revenue growth may underdeliver versus prior expectations. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Management also highlighted competitive pressure in electrophysiology and a more cautious near-term operating backdrop, which added to investor concerns and helped trigger the stock’s sharp decline. Boston Scientific (BSX) slides after management cuts 2026 growth outlook
• Neutral Sentiment: On the positive side, Boston Scientific still has an active product pipeline, and one recent device trial reported strong efficacy, which could support the longer-term growth story if commercial adoption follows. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Neutral Sentiment: The company also deployed capital into a large private-company stake, which may appeal to long-term strategic investors but is not the main driver of the stock’s move today. Boston Scientific Is Betting $1.5 Billion on a Massive Market — and Wall Street Is Paying Attention

Insider Activity

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Boston Scientific

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth about $26,000. Murphy & Mullick Capital Management Corp raised its position in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the period. Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth about $26,000. United Community Bank raised its position in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the period. Finally, Colonial Trust Co SC raised its position in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 12.7%

Shares of BSX stock opened at $50.34 on Thursday. The stock has a market cap of $74.82 billion, a P/E ratio of 21.06, a PEG ratio of 1.06 and a beta of 0.62. Boston Scientific has a 52 week low of $50.04 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company’s fifty day simple moving average is $61.13 and its two-hundred day simple moving average is $79.19.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts predict that Boston Scientific will post 3.38 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.